KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Asset Writedowns and Impairment (2018 - 2019)

Opko Health (OPK) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with $91.7 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Asset Writedowns and Impairment rose 321.27% year-over-year to $91.7 million, compared with a TTM value of $91.7 million through Sep 2020, up 308.97%, and an annual FY2025 reading of $1.0 million, changed N/A over the prior year.
  • Asset Writedowns and Impairment was $91.7 million for Q4 2019 at Opko Health, up from $655000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $91.7 million in Q4 2019 and bottomed at -$8.3 million in Q4 2015.
  • Average Asset Writedowns and Impairment over 3 years is $16.3 million, with a median of $655000.0 recorded in 2019.
  • Peak annual rise in Asset Writedowns and Impairment hit 15904.17% in 2015, while the deepest fall reached 853.9% in 2015.
  • Year by year, Asset Writedowns and Impairment stood at -$8.3 million in 2015, then skyrocketed by 362.13% to $21.8 million in 2018, then surged by 321.27% to $91.7 million in 2019.
  • Business Quant data shows Asset Writedowns and Impairment for OPK at $91.7 million in Q4 2019, $655000.0 in Q1 2019, and $21.8 million in Q4 2018.